- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Trial completion, Trial primary completion date: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Mar 8, 2016
P1/2, N=115, Completed,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Trial primary completion date: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Dec 9, 2015
P1/2, N=115, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Apr 2015 Trial primary completion date: Aug 2015 --> Dec 2015
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Enrollment closed: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=115, Active, not recruiting,
Trial primary completion date: Aug 2015 --> Dec 2015 Enrolling by invitation --> Active, not recruiting
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Enrollment open: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Jan 6, 2015
P1/2, N=115, Enrolling by invitation,
Enrolling by invitation --> Active, not recruiting Suspended --> Enrolling by invitation
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Trial suspension: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Dec 17, 2014
P1/2, N=115, Suspended,
Suspended --> Enrolling by invitation Recruiting --> Suspended
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
Enrollment open: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Dec 10, 2014
P1/2, N=115, Recruiting,
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||||||||| Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
New P1/2 trial: VSV-ZEBOV Geneva Vaccine Trial (clinicaltrials.gov) - Nov 11, 2014
P1/2, N=115, Not yet recruiting,
|
